Bevacizumab for recurrent ependymoma

od Green, R M., Cloughesy, T F., Stupp, R, DeAngelis, L M., Woyshner, E A., Ney, D E., Lassman, A B.
Izdano 2009

Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma

od Gupta, A., Young, R.J., Karimi, S., Sood, S., Zhang, Z., Mo, Q., Gutin, P.H., Holodny, A.I., Lassman, A.B.
Izdano 2011

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

od Iwamoto, F M., Abrey, L E., Beal, K, Gutin, P H., Rosenblum, M K., Reuter, V E., DeAngelis, L M., Lassman, A B.
Izdano 2009

Correction to: (18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors

od Michaud, Laure, Beattie, B. J., Akhurst, T., Dunphy, M., Zanzonico, P., Finn, R., Mauguen, A., Schöder, H., Weber, W. A., Lassman, A. B., Blasberg, R.
izdano v Eur J Nucl Med Mol Imaging (2019)

(18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors

od Michaud, Laure, Beattie, B. J., Akhurst, T., Dunphy, M., Zanzonico, P., Finn, R., Mauguen, A., Schöder, H., Weber, W. A., Lassman, A. B., Blasberg, R.
izdano v Eur J Nucl Med Mol Imaging (2019)

OS07.5 Interim analysis data from Phase 2 study on efficacy, safety & intratumoral pharmacokinetics of oral Selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)

od Lassman, A. B., Bent, M. J. V. D., Wen, P. Y., Walenkamp, A., Plotkin, S., Kung, A., Gardner, H., Shacham, S., Chudnovsky, A., Mau-Sorensen, P. M.
izdano v Neuro Oncol (2017)

P06.02 Transcriptional profiling to identify determinants associated with response to ABT-414 in patients with glioblastoma

od van den Bent, M., Gan, H., Reardon, D. A., Papadopoulos, K. P., Merrell, R., Kumthekar, P., Roberts-Rapp, L., Holen, K., Ansell, P., Lassman, A. B.
izdano v Neuro Oncol (2016)

P08.19 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)

od van den Bent, M., Gan, H. K., Lassman, A. B., Kumthekar, P., Butowski, N., Lwin, Z., Nabors, L. B., Simes, J., Holen, K., Reardon, D. A.
izdano v Neuro Oncol (2016)

P01.071 Genomic profiling identifies tubulin mutations that may predict response to depatuxizumab mafodotin in patients with glioblastoma

od Lassman, A B, Roberts-Rapp, L, He, L, Lu, X, Zha, Z, Bhathena, A, Ansell, P J, Gan, H K, Scott, A M, van den Bent, M
izdano v Neuro Oncol (2018)

Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme

od Chow, D.S., Qi, J., Guo, X., Miloushev, V.Z., Iwamoto, F.M., Bruce, J.N., Lassman, A.B., Schwartz, L.H., Lignelli, A., Zhao, B., Filippi, C.G.
izdano v AJNR Am J Neuroradiol (2014)

PL3.5 Efficacy and safety of selinexor in recurrent glioblastoma

od Lassman, A B, Wen, P Y, van den Bent, M, Plotkin, S R, Walenkamp, A, Green, A, Huang, X, Karla Rodriguez-Lopez, K, Kauffman, M G, Shacham, S, Mau-Soerensen, M
izdano v Neuro Oncol (2019)

OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

od Lassman, A B, Sepúlveda-Sánchez, J M, Cloughesy, T, Gil-Gil, J M, Puduvalli, V K, Raizer, J, De Vos, F Y, Wen, P Y, Butowski, N, Clement, P, Groves, M D, Belda-Iniesta, C, Steward, K, Moran, S, Ye, Y, Roth, P
izdano v Neuro Oncol (2019)